Biofrontera AG is a German biopharmaceutical company that focuses on developing and selling dermatological drugs and medical cosmetics for the care, protection, and treatment of skin. With almost 200 employees worldwide, the company's lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since 2016. Biofrontera AG also sells prescription medication XepiTM for impetigo treatment in the US and the dermocosmetics series Belixos® in the EU for specialized care of damaged or diseased skin.